February 8, 2018 | Arizona Biltmore | Phoenix, Arizona


Cheryl Corcoran, M.S., M.D.
Associate Professor
Program Leader in Psychosis Risk
Department of Psychiatry
Icahn School of Medicine, Mount Sinai Hospital, New York, NY

Cheryl Corcoran, M.D. is a graduate of Harvard College and Harvard Medical School. She completed her internship and residency in adult psychiatry at The Cambridge Health Alliance, a research fellowship in Schizophrenia Research at Columbia University, and a Masters degree in biostatistics (Patient-Oriented Research track) at the Mailman School of Public Health.

Dr. Corcoran is Associate Professor of Psychiatry and Program Leader in Psychosis Risk at the Icahn School of Medicine at Mount Sinai in New York City.

Dr. Corcoran’s clinical and research expertise is in the early stages of schizophrenia, including the period of clinical high risk (CHR) for psychosis and first episode psychosis (FEP). Her research focuses on ethics and phenotypic characterization, including the use of automated natural language processing (NLP) methods to characterize disturbance in language across stages of schizophrenia, a project conducted in collaboration with Dr. Guillermo Cecchi of IBM. Dr. Corcoran co-developed the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS) in 1999, and founded a prospective prodromal cohort study in 2005. She has authored 89 manuscripts on schizophrenia, encompassing automated speech analyses, sensory processing, social cognition, neuroimaging, clinical correlates, cannabis/stress exposures, nosology, stigma, and ethics. More than 50 of her publications focus on the prodromal phase that precedes the onset of schizophrenia.

Presentation: Can Schizophrenia Be Prevented?

Dr. Corcoran will review the current state of research on the prodromal phase of schizophrenia, attenuated psychosis syndrome, predictors of schizophrenia onset and functional outcome, and preventive interventions.

Learning objectives:

• Learn how to identify the clinical risk syndrome for psychosis
• Describe cognitive markers of psychosis risk, including language disturbance
• Understand the evidence that supports preventive therapies, and recognize targets for preventive intervention